Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Louis Sanfilippo, MD

Psychiatrist
Louis Sanfilippo, MD
Member of the Healthcare Council

Louis Sanfilippo, MD, is an Assistant Clinical Professor of Psychiatry at Yale School of Medicine and in private practice. He has served management and scientific advisory roles for Cenestra Health, a biotech company focused on developing empirically validated nutraceutical products. Dr. Sanfilippo has interest in early and middle stage drug development/intellectual property platforms for treating CNS disorders. He teaches psychopharmacology to Yale psychiatry residents with a focus on antidepressants, mood stabilizers, antipsychotics, and stimulants. Dr. Sanfilippo has clinical expertise in treatment of anxiety, mood disordes, and ADHD in adults, college students, athletes, and executives. He has published on a wide range of topics, including principles of psychopharmacology in young adults, mood disorders and suicide, psychotic disorders, forensic psychiatry, the philosophy of mind, and a psychiatry review for medical students. Dr. Sanfilippo has spoken on sports psychiatry and ADHD. (This is me - Update Profile)


Employment History
2001 - present Psychiatrist
Louis Sanfilippo, MD
2001 - 2006 Staff Psychiatrist; Assistant Clinical Professor
Yale University Health Services

GLG Study Groups with Louis Sanfilippo, MD(?)

View All Study Groups with Louis Sanfilippo, MD

GLG NewsSM Analyses by Louis Sanfilippo, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
One Drug, Many Uses -- Mostly a Very Good Idea | 07-03-2008
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Lundbeck Reveals Mechanism of Action of its “Mixed Serotonin Modulator and Stimulator” Antidepressant LuAA21004 | 06-30-2008
Analysis of: Interim report for the first quarter of 2008 - strong growth in sales and profits | www.lundbeck.com
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...

BrainCells Novel Antidepressant: Targeting Neurogenesis but not Serotonin? | 05-21-2008
Analysis of: BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety | www.medicalnewstoday.com
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

It’s not clear just how BrainCells’ BCI-540 works but the company claims the drug acts by way of promoting neurogenesis without an effect on serotonin neurotransmission.   While SSRI’s also promote neurogenesis, a downstream effect believed to favorably impact mood and anxiety, they obviously...

Abbott Targets Adult ADHD with Nicotinic Drug, Shows Strong CNS Pipeline | 05-13-2008
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

Abbott’s Neuronal Nicotinic Receptor (NNR) partial agonist platform is an innovative target for ADHD and potentially other CNS disorders.  The Phase II data on ABT-089 suggests efficacy for adult ADHD with good safety/tolerability.  NNRs will not have the kind of effect size seen with stimulants...

View All GLG News SM Analyses by Louis Sanfilippo, MD

GLG InstituteSM Seminars with Louis Sanfilippo, MD(?)

Request a project with Louis Sanfilippo, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics